Avascular Necrosis Market Size, Trends And Forecast To 2031
Posted by pooja on August 3rd, 2022
Avascular necrosis (AVN) also named as aseptic necrosis, osteonecrosis, or ischemic bone necrosis, is a condition bringing about the death of bone cells because of lack of blood supply. It frequently leads fall of the joint surface and consequent joint inflammation because of an irregular joint surface. Avascular necrosis influences the closures (epiphysis) of long bones, for example, upper humerus, femur, and bones of lower leg joint.
Increased consumption of alcohol for a long time, heavy dose of systematic corticosteroid utilize are the significant hazard factors for avascular necrosis.
Other serious factors or conditions related with non-traumatic osteonecrosis incorporate cancer, autoimmune illness, Gaucher disorder, decompression illness (Caisson ailment), HIV infection, pancreatitis, and blood issue, for example, sickle cell infection. Certain treatment including chemotherapy and radiation treatment can cause osteonecrosis as well. Besides, individuals who have experienced organ transplants are at high risk of osteonecrosis.
Major players operating in the global avascular necrosis market are Boehringer Ingelheim GmbH, Bone Therapeutics, Bayer AG, Ethicon Inc., Enzo Biochem Inc., Eli Lilly and Company, Integra LifeSciences Corporation, Grifols SA, K-Stemcell Co Ltd., Merck KGaA, Medtronic Plc, Pfizer Inc., Stryker Corporation, Sanofi SA, Zimmer Biomet Holdings, and Wright Medical Group N.V.
Request Sample Copy @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4203
About TMR Research
Like it? Share it!
About the Authorpooja
Joined: July 27th, 2022
Articles Posted: 199
More by this author